NBIX - Neurocrine Biosciences EPS misses by $0.16 misses on revenue

Neurocrine Biosciences (NASDAQ:NBIX): Q3 Non-GAAP EPS of $0.64 misses by $0.16; GAAP EPS of $0.23 misses by $0.34. Revenue of $296M (+14.5% Y/Y) misses by $1.49M. Press Release Net product sales for the third quarter of 2021 were $287 million and $285 million on an inventory adjusted basis Record total prescriptions achieved during the third quarter 2021 reflecting higher customer demand and increased commercial activities New prescriptions increased throughout the third quarter, reaching their highest levels since March 2020

For further details see:

Neurocrine Biosciences EPS misses by $0.16, misses on revenue